ArticleMemorias do Instituto Oswaldo Cruz2015
Reaching for the Holy Grail: insights from infection/cure models on the prospects for vaccines for Trypanosoma cruzi infection.
Article in Memorias do Instituto Oswaldo Cruz, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Long-Term Parasitological Clearance and Cardiac Progression inTropical medicine and infectious disease · 2026Article
- Highly cross-reactive and competent effectors dominate the CD8+ T cell response in Trypanosoma cruzi infection.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- The importance of persistence and dormancy in Trypanosoma cruzi infection and Chagas disease.Current opinion in microbiology · 2025Review
- Natural infection of Trypanosoma Cruzi in client-owned-dogs from rural Yucatan, Mexico.Scientific reports · 2025Article
- Vaccination with parasite-specific TcTASV proteins combined with recombinant baculovirus as a delivery platform protects against acute and chronicFrontiers in cellular and infection microbiology · 2024Article
- Subunit nanovaccine elicited T cell functional activation controls Trypanosoma cruzi mediated maternal and placental tissue damage and improves pregnancy outcomes in mice.NPJ vaccines · 2023Article
- Article
- Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers for monitoring parasitological cure.PLoS neglected tropical diseases · 2022Article
- Chronic Chagas Disease-the Potential Role of Reinfections in Cardiomyopathy Pathogenesis.Current heart failure reports · 2022Review
- Incomplete Recruitment of Protective T Cells Is Associated with Trypanosoma cruzi Persistence in the Mouse Colon.Infection and immunity · 2022Article
- Safety and immunogenicity of a recombinant vaccine against Trypanosoma cruzi in Rhesus macaques.Vaccine · 2020Article
- Drug-cured experimental Trypanosoma cruzi infections confer long-lasting and cross-strain protection.PLoS neglected tropical diseases · 2020Article
- Experimental Nanovaccine Offers Protection Against Repeat Exposures toFrontiers in immunology · 2020Article
- Article
- Highly competent, non-exhausted CD8+ T cells continue to tightly control pathogen load throughout chronic Trypanosoma cruzi infection.PLoS pathogens · 2018Article
- The protein family TcTASV-C is a novel Trypanosoma cruzi virulence factor secreted in extracellular vesicles by trypomastigotes and highly expressed in bloodstream forms.PLoS neglected tropical diseases · 2018Article
- Engineered trivalent immunogen adjuvanted with a STING agonist confers protection againstNPJ vaccines · 2017Article
- Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps.Advances in parasitology · 2017Review
- Chagas Disease: A Solvable Problem, Ignored.Trends in molecular medicine · 2016Article
- CD8+ T cells in Trypanosoma cruzi infection.Seminars in immunopathology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Prevention of Trypanosoma cruzi infection in mammals likely depends on either prevention of the invading trypomastigotes from infecting host cells or the rapid recognition and killing of the newly infected cells by T. cruzi-specific T cells. We show here that multiple rounds of infection and cure (by drug therapy) fails to protect mice from reinfection, despite the generation of potent T cell responses. This disappointing result is similar to that obtained with many other vaccine protocols used in attempts to protect animals from T. cruzi infection. We have previously shown that immune recognition of T. cruzi infection is significantly delayed both at the systemic level and at the level of the infected host cell. The systemic delay appears to be the result of a stealth infection process that fails to trigger substantial innate recognition mechanisms while the delay at the cellular level is related to the immunodominance of highly variable gene family proteins, in particular those of the trans-sialidase family. Here we discuss how these previous studies and the new findings herein impact our thoughts on the potential of prophylactic vaccination to serve a productive role in the prevention of T. cruzi infection and Chagas disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.